Page 2 - Pharma Companies

Apollo Pharmacy targets 100 mn customers in 5 yrs, 2 new stores daily: CEO

Apollo Pharmacy plans to open two new stores every day, targeting to grow its customer base to 10 crore within the next five years, its CEO P Jayakumar said on Friday. The omni-channel pharmacy network, which has crossed the 7,000-store mark with the opening of its latest store in Ayodhya, Uttar Pradesh, aims to strengthen the neighbourhood pharmacy reach. "We will continue to expand by opening two new stores every day and grow our customer base to 100 million within the next five years, ensuring that the highest-quality medicines remain within everyone's reach," Jayakumar said in a statement. Apollo HealthCo operates Apollo Pharmacy that serves users across over 19,000 pin codes. Apollo HealthCo Executive Chairperson Shobana Kamineni said at present, Apollo Pharmacy serves over one million orders every day. "The 7,000-store milestone reflects the scale Apollo has built and the trust families place in us. We will continue to deepen access, strengthen India's neighbourhood pharmacy

Aurobindo incurring loss at China Plant, hopes to achieve break-even by Q4

Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian. The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, he said. "China (plant), as on date in the quarter, I will be incurring a loss of around maybe a million dollars, but, probably, we will be able to achieve the break-even between Q3 and Q4 and after that, China will start moving up in the overall contributing to the growth of the EBITDA growth," Subramanian said in an analyst call. The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals, he stated. The site is on track to deliver EBITDA break-even by Q3-Q4 FY26, reinforcing its strategic importance to the global network, he added.

Sudeep Pharma IPO opens Nov 21: Know key strengths, risks before you invest

Sudeep Pharma IPO will be offered at a price band of ₹563 to ₹593 per share

Sudeep Pharma IPO opens Nov 21; sets price band at ₹549-577; Check details

Sudeep Pharma IPO will open for public bidding on Friday, November 21 and close on Tuesday, November 25, 2025

Centre brings draft rules to debar drugmakers who provide fake information

The health ministry proposes new provisions under the Drugs Rules, 1945, allowing regulators to bar applicants who submit fake or misleading data for approvals

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Glenmark recalls product in US over manufacturing issue: USFDA

Drugmakers Glenmark and Dr Reddy's Laboratories are recalling products in the US due to manufacturing issues, according to the US Food and Drug Administration (USFDA). As per its latest Enforcement Report, the US health regulator noted that a US-based unit of Glenmark Pharmaceuticals is recalling 26,928 packs of oral contraceptive medication in the US. Mahwah, New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the affected lot of Viorele, Desogestrel and Ethinyl Estradiol (USP, 0.15 mg/ 0.02 mg) and Ethinyl Estradiol tablets due to "failed impurities/degradation specifications." The affected lot was produced at Mumbai-headquartered drug maker's Goa manufacturing facility. The drug firm issued the Class II nationwide recall on September 3, 2025. USFDA stated that a US-based subsidiary of Dr Reddy's Laboratories is recalling the medication used to provide muscle relaxation during surgery. Princeton, New Jersey-based Dr. Reddy's Laboratories, Inc is recalling 571 vials o

Centre refuses deadline extension for pharma firms after Coldrif deaths

The decision to turn down requests from drug manufacturers for more time came after it was highlighted that Sresan Pharmaceutical, the company that produced Coldrif, did not upgrade its facilities

Graph AI raises $3 mn from Bessemer to target $8 bn drug safety market

California-based Graph AI raised $3 million in seed funding led by Bessemer Venture Partners to scale its AI-driven pharmacovigilance platform for global drug safety and compliance

WHO alert on 3 'toxic' syrups: Which pharma companies are under the scanner?

The World Health Organization has issued a global alert after identifying three toxic cough syrups in India that have been linked to the deaths of several children in Madhya Pradesh and Rajasthan.

Last day! Rubicon Research IPO ends today; subscription up 28x, NIIs lead

Rubicon Research's unlisted shares were trading at ₹580, reflecting a grey market premium of ₹95 or 19.6 per cent above the issue price of ₹485

Cough syrup deaths: Probe into Coldrif manufacturer exposes TNFDA lapses

The investigation against the Kanchipuram-based manufacturer of Coldrif cough syrup, linked to the deaths of children in Madhya Pradesh, has brought to light lapses by the Tamil Nadu Food and Drug Administration in enforcing basic regulatory norms, CDSCO sources said. Licensed in 2011 by the Tamil Nadu Food and Drug Administration (TNFDA), Sresan Pharma continued operations unchecked for over a decade despite its dismal infrastructure and multiple violations of national drug safety rules, they said. A recent inspection by the Central Drugs Standard Control Organisation (CDSCO) exposed the unit's appalling conditions and total non-compliance with Good Manufacturing Practices (GMP), the sources said. "The CDSCO has not been involved in any of the audits at Sresan Pharma. Since the CDSCO was not involved and the state FDA did not inform the CDSCO about this company in any way, this company was not part of any of the CDSCO databases," a source said. TNFDA officials could not be reached

AstraZeneca to strike landmark drug price deal with Trump administration

The deal is expected to be announced at the White House on Friday, said the people, who spoke on condition of anonymity because the plans are not yet public

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Lupin has received USFDA approval for generic Lenalidomide capsules in six strengths, adding to competition in the US oncology market for Bristol-Myers Squibb's Revlimid

Mankind joins hands with OpenAI to institutionalise AI in operations

"GPT-powered dashboards will be used to provide real-time, data-driven insights across R&D, supply chain and commercial operations," a company executive told Business Standard

India's bulk drug makers start preparing for Ozempic patent expiry

From local giants Dr Reddy's Laboratories Ltd. to suppliers like Macleods Pharmaceuticals Ltd., Indian firms are preparing to make bulk drugs

NPPA asks pharma, medtech firms to cut prices after GST rate reduction

NPPA directs pharma and medical device makers to revise MRPs after GST cut to 5 per cent, while making relabelling of old stock voluntary subject to compliance

Biocon inaugurates first manufacturing facility in New Jersey's Cranbury

Biocon Ltd on Thursday said it has inaugurated its first manufacturing facility in the US, located in Cranbury, New Jersey. The company's wholly-owned subsidiary, Biocon Generics Inc. (BGI), operates the plant. Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc in 2023 and has since invested over USD 30 million to establish a plant with an annual production capacity of 2 billion tablets. A few products have already been commercialised from the site, with several more in the pipeline, the Bengaluru-based firm said in a statement. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint, it added. "Biocon's first USFDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion," Kiran Mazumdar-Shaw, Chairperson of Biocon Group, said. The facility reflects the company's long-term commitment to deeper engagement with healthcare provide

Glenmark starts multi-nation Phase 3 clinical trials for lung cancer drug

Glenmark Pharmaceuticals on Friday said it has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel drug for third-stage non-small cell lung cancer. The company said it has received approval from the Drugs Controller General of India to begin patient enrolment and dosing in the country. In parallel, the drug firm has submitted a clinical trial application in Russia and is preparing to open additional clinical trial sites in Brazil and Mexico, Glenmark said in a statement. The randomised, multi-centre, Phase 3 trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with third-stage non-small cell lung cancer (NSCLC). Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC comprising around 80-85 per cent of cases. "By advancing this trial across multiple geographies, we are reinforcing our commitment to transforming the standard of care in Stage III NSCLC and addressing one of the grea

Ethical marketing code: Cost of compliance may rise for drug, device firms

UCPMPD 2024 boosts transparency and ethics, but smaller firms may struggle with higher costs and reporting demands